长期抗CD20治疗中高表达IL1B的单核细胞簇表型变化
该研究对多发性硬化(MS)患者和健康对照(HC)的外周血单个核细胞(PBMC)进行靶向单细胞转录组与表位测序,并部分样本行光谱流式验证。发现一个高表达IL1B的经典单核细胞簇在HC中占PBMC的8.1%,未治疗MS患者中降至0.8%,抗CD20治疗后其丰度增加6倍并出现促炎基因表达与MYC相关调控网络改变。
要点
- 未治疗MS患者外周血IL1B高表达单核细胞簇减少,可能与其中枢神经系统浸润表型相关。
- 抗CD20治疗后该单核细胞簇丰度增加6倍,促炎基因表达和MYC相关调控网络发生变化。
- 该单核细胞群的变化可能参与抗CD20治疗的非B细胞相关效应。
核心结论
- 单细胞分析识别出一个独特的外周IL1B高表达单核细胞簇,其表型提示中枢神经系统浸润能力,可解释未治疗MS患者血中丰度低于抗CD20治疗患者。
- 该单核细胞群的治疗相关变化可能贡献抗CD20治疗的非B细胞相关效应。
研究设计与样本
- 对64份血液样本(MS患者基线及抗CD20治疗后3个时间点,以及健康对照)的PBMC进行靶向单细胞转录组和表位测序。
- 其中15份样本进行多色光谱流式细胞术验证。
主要发现
- 鉴定出一个经典单核细胞亚群,其IL1B表达显著高,表达CXCL8、CCL3、CCL4和TNFα等促炎趋化因子和细胞因子基因,是细胞间通讯网络中的主要细胞传递亚群。
- 该IL1B高表达单核细胞簇在健康对照中占PBMC的8.1%,在未治疗MS患者中占0.8%。
- MS患者来源的IL1B高表达单核细胞高表达CXCR4,Gene Ontology分析提示其具有中枢神经系统浸润能力,可能受LEF1调控。
- 抗CD20治疗后,IL1B高表达单核细胞的促炎基因表达和MYC相关调控网络发生改变,其在血液中的丰度增加6倍。
临床怎么用
- 监测外周血IL1B高表达单核细胞簇可能有助于理解MS疾病活动及抗CD20治疗的非B细胞效应。
- 抗CD20治疗期间该单核细胞簇促炎表型改变,提示需关注其与治疗应答及中枢神经系统浸润的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to investigate disease-related and anti-CD20 therapy-related changes in peripheral blood mononuclear cells (PBMCs) from multiple sclerosis (MS) patients compared to healthy controls (HC) using multi-omics single-cell analysis. METHODS: Targeted single-cell sequencing of transcriptomes and epitopes was performed on PBMCs isolated from 64 blood samples collected from MS patients at baseline and at 3 time points following anti-CD20 treatment, alongside HC. Multicolor spectral flow cytometry was performed on 15 of the samples. RESULTS: Cell cluster analysis identified a subpopulation of classical monocytes with significantly high interleukin-1 beta (IL1B) expression and a pro-inflammatory profile compared to other monocyte clusters. This monocyte cluster expressed genes of pro-inflammatory chemokines and cytokines, such as CXCL8, CCL3, CCL4, and TNFα and was a major cell transmitter subset within the intercellular communication network. The IL1Bhigh monocyte cluster was prevalent in HC (8.1% of PBMCs), but reduced in untreated MS patients (0.8% of PBMCs). High CXCR4 expression and Gene Ontology-term analysis indicated that IL1Bhigh monocytes from MS patients had central nervous system (CNS)-infiltrating abilities in contrast to HC, likely regulated by LEF1. After anti-CD20 treatment, IL1Bhigh monocytes showed changes in pro-inflammatory gene expression and MYC-associated regulatory networks, and their abundance increased 6-fold in the blood. INTERPRETATION: Our single-cell analysis identified a unique peripheral IL1Bhigh monocyte cluster with a suggested CNS-infiltrating cellular phenotype that may explain its lower abundance in the blood of untreated compared to anti-CD20 treated MS patients. Treatment-associated changes in this population may contribute to the non-B cell related effects of anti-CD20 therapy. ANN NEUROL 2025;98:1283-1298.
引用
- Waede M, Kingo C, Damsbo K, et al. Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy. Ann Neurol. 2025. PMID: 40879186. doi:10.1002/ana.78004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。